Study S002753

Randomized,Double-blind,Placebo-controlled,Dose-escalating Phase I,Healthy Subjects Study of JY09,a Recombinant GLP-1 Receptor Agonist

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02971722
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: UNKNOWN
Enrollment: 26
Start: 2016-12
Primary completion: 2017-05
Lead sponsor: Beijing Dongfang Biotech Co., Ltd.
Conditions: Healthy
Interventions: DRUG:JY09; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Pharmacokinetics (PK) [Baseline through day29 of period]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021148	Exenatide and weight loss. Bradley DP, Nutrition (Burbank, Los Angeles County, Calif.)	2010	Narrative review	PMID 20152707 DOI	registry reference BACKGROUND:20152707
R0021594	Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. Thorkildsen C, The Journal of pharmacology and experimental therapeutics	2003	Preclinical	PMID 12975499 DOI	registry reference BACKGROUND:12975499